RecruitingPhase 2NCT07415031

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)


Sponsor

Mirati Therapeutics Inc.

Enrollment

170 participants

Start Date

May 6, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adagrasib, a drug called Cetuximab, and others for people with solid tumors. The study is currently recruiting participants at 77 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdagrasib

Specified dose on specified days

DRUGPembrolizumab

Specified dose on specified days

DRUGCetuximab

Specified dose on specified days

DRUGPemetrexed

Specified dose on specified days

DRUGDocetaxel

Specified dose on specified days

DRUGIrinotecan

Specified dose on specified days

DRUGLeucovorin

Specified dose on specified days

DRUGOxaliplatin

Specified dose on specified days

DRUGFluorouracil

Specified dose on specified days


Locations(100)

Local Institution - 0005

Phoenix, Arizona, United States

Southern California Permanente Medical Group

Bellflower, California, United States

Local Institution - 0082

Long Beach, California, United States

Local Institution - 0003

Newark, Delaware, United States

Florida Cancer Specialists - North

St. Petersburg, Florida, United States

Local Institution - 0112

Wichita, Kansas, United States

Local Institution - 0092

Boston, Massachusetts, United States

Local Institution - 0080

Boston, Massachusetts, United States

Mayo Clinic in Rochester, Minnesota

Rochester, Minnesota, United States

Local Institution - 0073

Saint Paul, Minnesota, United States

Local Institution - 0036

Omaha, Nebraska, United States

Oncology Associates Of Oregon, Pc

Eugene, Oregon, United States

Local Institution - 0023

Germantown, Tennessee, United States

Texas Oncology-Bedford

Bedford, Texas, United States

Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, United States

Texas Oncology - DFW

Grapevine, Texas, United States

Local Institution - 0013

Bellingham, Washington, United States

Local Institution - 0093

St Leonards, New South Wales, Australia

Local Institution - 0033

Ghent, Belgium

Local Institution - 0072

Vancouver, British Columbia, Canada

Local Institution - 0037

Beijing, Beijing Municipality, China

Local Institution - 0045

Xiamen, Fujian, China

Local Institution - 0042

Zhengzhou, Henan, China

Local Institution - 0038

Changsha, Hunan, China

Local Institution - 0046

Nanjing, Jiangsu, China

Local Institution - 0048

Nanchang, Jiangxi, China

Local Institution - 0049

Shenyang, Liaoning, China

Local Institution - 0039

Jinan, Shandong, China

Local Institution - 0047

Linyi, Shandong, China

Local Institution - 0043

Shanghai, Shanghai Municipality, China

Local Institution - 0040

Chengdu, Sichuan, China

Local Institution - 0044

Hangzhou, Zhejiang, China

Local Institution - 0041

Xi'an, China

Local Institution - 0076

Nice, Alpes-Maritimes, France

Local Institution - 0086

Nice, Alpes-Maritimes, France

Local Institution - 0074

Strasbourg, Alsace, France

Local Institution - 0103

Pessac, Aquitaine, France

Local Institution - 0091

Besançon, Doubs, France

Local Institution - 0065

La Tronche, Isère, France

Local Institution - 0063

Saint-Herblain, Loire-Atlantique, France

Local Institution - 0050

Saint-Herblain, Loire-Atlantique, France

Local Institution - 0032

Angers, Maine-et-Loire, France

Local Institution - 0090

Bron, Rhône, France

Local Institution - 0075

Gleizé, Rhône, France

Local Institution - 0051

Poitiers, Vienne, France

Local Institution - 0085

Créteil, France

Local Institution - 0059

Marseille, France

Local Institution - 0058

Quimper, France

Local Institution - 0078

Saint-Mandé, France

Local Institution - 0077

Tours, France

Local Institution - 0061

Paris, Île-de-France Region, France

Local Institution - 0012

München, Germany

Local Institution - 0081

Athens, Attikí, Greece

Local Institution - 0022

Attiki, Greece

Local Institution - 0087

Thessaloniki, Greece

Local Institution - 0089

Budapest, Hungary

Local Institution - 0067

Budapest, Hungary

Local Institution - 0055

Jerusalem, Jerusalem, Israel

Local Institution - 0106

Tel Aviv, Israel

Local Institution - 0019

Rome, Roma, Italy

Local Institution - 0053

Bologna, Italy

Local Institution - 0054

Florence, Italy

Local Institution - 0052

Meldola, Italy

Local Institution - 0021

Milan, Italy

Local Institution - 0107

Milan, Italy

Local Institution - 0020

Orbassano, Italy

Local Institution - 0079

Pesaro, Italy

Local Institution - 0031

Roma, Italy

Local Institution - 0026

Terni (Perugia), Italy

Local Institution - 0110

Tōon, Ehime, Japan

Local Institution - 0056

Breda, North Brabant, Netherlands

Local Institution - 0034

Amsterdam, Netherlands

Local Institution - 0035

Harderwijk, Netherlands

Local Institution - 0071

Utrecht, Netherlands

Local Institution - 0102

Gdansk, Poland

Local Institution - 0101

Lublin, Poland

Local Institution - 0014

Lisbon, Lisbon District, Portugal

Local Institution - 0060

Craiova, Dolj, Romania

Local Institution - 0088

Singapore, Central Singapore, Singapore

Local Institution - 0069

Gyeonggi-do, South Korea

Local Institution - 0070

Seoul, South Korea

Local Institution - 0068

Seoul, South Korea

Local Institution - 0007

A Coruña, A Coruña [La Coruña], Spain

Local Institution - 0011

Palma, Balears [Baleares], Spain

Local Institution - 0010

Barcelona, Barcelona [Barcelona], Spain

Local Institution - 0006

Badalona, Barcelona, Spain

Local Institution - 0030

Santander, Cantabria, Spain

Local Institution - 0024

Madrid, Madrid, Comunidad de, Spain

Local Institution - 0009

Pamplona, Navarre, Spain

Local Institution - 0084

Valencia, Valenciana, Comunitat, Spain

Local Institution - 0029

Barcelona, Spain

Local Institution - 0027

Córdoba, Spain

Local Institution - 0083

Madrid, Spain

Local Institution - 0015

Madrid, Spain

Local Institution - 0062

Madrid, Spain

Local Institution - 0018

Málaga, Spain

Local Institution - 0008

Seville, Spain

Local Institution - 0115

London, London, City of, United Kingdom

Local Institution - 0113

Birmingham, United Kingdom

Local Institution - 0114

Leicester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07415031


Related Trials